Modulating T-cell-based cancer immunotherapy via particulate systems

  • Duy Hieu Truong, Thi Thu Phuong Tran, Hanh Thuy Nguyen, Cao Dai Phung, Tung Thanh Pham, Chul Soon Yong, Jong Oh Kim, Tuan Hiep Tran
  • Journal of Drug Targeting, June 2018, Taylor & Francis
  • DOI: 10.1080/1061186x.2018.1474360

We summarize several engineered particles to manipulate the responses of T cells to treat cancer.

What is it about?

Immunotherapy holds tremendous promise for improving cancer treatment in which an appropriate stimulator may naturally trigger the immune system to control cancer. Up-to-date, adoptive T-cell therapy has received two new FDA approvals that provide great hope for some cancer patient groups. Nevertheless, expense and safety-related issues require further study to obtain insight into targets for efficient immunotherapy. The development of material science was largely responsible for providing a promising horizon to strengthen immunoengineering. In this review, we focus on T-cell characteristics in the context of the immune system against cancer and discuss several approaches of exploiting engineered particles to manipulate the responses of T cells and the tumour microenvironment.

Read Publication

The following have contributed to this page: Mr Duy Hieu Truong and Professor Jong Oh Kim